AVAPS-AE Mode of Therapy
DeviceAVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
NCT Number: NCT01368614
The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed with Obesity Hypoventilation syndrome (OHS).
The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will yield daytime gas exchange values which are equivalent or no worse when compared to using CPAP and bilevel PSV modes of ventilation in the OHS population.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
University of Arizona School of Medicine, Tucson, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
Currently cleared Non-Invasive Ventilation (NIV) therapy modality
Currently cleared NIV therapy modality
Time frame: Screening & 6 weeks
Daytime PaCO2 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.
Time frame: Screening & 6 weeks
Daytime Pa02 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.
Time frame: Screening & 6 weeks
The AHI is the number of apneas and hypopneas per hour of sleep. It will be evaluated during the screening sleep study and the 6 week follow up sleep study. AHI less than 5 is considered normal. For an Apnea-Hypopnea Index (or AHI) from 5 to 15 denotes mild sleep apnea. Fifteen to 30 is moderate, while a greater than 30 AHI is considered severe.
Time frame: Screening & 6 weeks
Epworth Sleepiness scale is a measure of daytime sleepiness. It is a series of 8 questions answered on a scale of 0 to 3, 0 being no chance of dozing and 3 being a high chance of dozing. The range of the scale is 0 to 24. The higher the total score, the higher the chance of falling asleep.
Time frame: Screening & 6 weeks
The SRIQ is a 49 question survey. This survey asks questions about the past week. It is answered on a scale of -2 to 2 and converted to 1 to 5, 1 is completely untrue and 5 is always true. The questionnaire is broken down into 7 sections when scoring: respiratory complaints, physical functioning, attendant systems and sleep, social relationships, anxiety, psychological well-being and social functioning. Once each scale score is calculated. The average score can be calculated by taking the mean of the subscales. This process of transformation produces a score between 0 and 100 with higher values indicating a better health-related quality of life according to content of the scale.
Time frame: 6 weeks
The average number of hours ventilator was used per each day used.
Time frame: 6 weeks
Average number of days used per week
Time frame: Screening & 6 weeks
Actigraphy is a method of measuring activity and sleep which is achieved by wearing a small watch-like device for an extended period of time. The data is intended to provide an objective measure of physical activity and sleep / week patterns during pre / post sleep studies and throughout the 6 weeks of home use.
Time frame: Screening & 6 weeks
Oxygen saturation measurements as determined by pulse oximetry
Time frame: Screening & 6 weeks
Nocturnal Transcutaneous Capnography is a non-invasive monitoring tool to measure ventilation over the night.
.
Time frame: Screening & 6 weeks
Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Total sleep time in each stage provides the average amount of time a participant was in that stage of sleep. This includes Stage 1, Stage 2, Stage 3/4, and Rapid Eye Movement (REM) sleep.
Time frame: Screening & 6 weeks
Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Sleep efficiency is measured by the total time a participant is spent asleep.
Time frame: Screening & 6 weeks
The arousal index is measured by the average number of arousals or awakenings a participant has over an hour of sleep.
Time frame: Screening & 6 weeks
Measurement of overnight oxygen saturation as measured by percentage of oxygen saturation (SpO2)
Time frame: Screening & 6 weeks
To measure trends of vigilance between the baseline screening assessment and the 6 week follow up visit comparing the three Arms/Groups. This measured how quickly participants reacted to visual stimulus. Reaction time is the latency at which the participant reacts to a visual stimulus > 100 ms.
Time frame: Screening & 6 weeks
Some users enrolled into the study required supplemental oxygen at different times during the day: at rest, during exertion and at night. The need for supplemental oxygen was compared at baseline and at 6 weeks.
Philips Respironics
Industry
Randomized Controlled Trial Evaluating the Feasibility of AVAPS-AE vs. CPAP vs.Bilevel Pressure Support Ventilation in Obesity Hypoventilation Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06142513
Apnea, Body Weight
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06486129
Apnea, Cardiac Output, Low
Košice, Slovakia
View Trial DetailsNCT04327336
Apnea, Body Weight
Cáceres, Spain
View Trial DetailsNCT04108819
Apnea, Dyssomnias
Baltimore, Maryland, United States
View Trial Details